These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1283 related articles for article (PubMed ID: 33510275)

  • 1. SARS-CoV-2 infection elicits a rapid neutralizing antibody response that correlates with disease severity.
    Trinité B; Tarrés-Freixas F; Rodon J; Pradenas E; Urrea V; Marfil S; Rodríguez de la Concepción ML; Ávila-Nieto C; Aguilar-Gurrieri C; Barajas A; Ortiz R; Paredes R; Mateu L; Valencia A; Guallar V; Ruiz L; Grau E; Massanella M; Puig J; Chamorro A; Izquierdo-Useros N; Segalés J; Clotet B; Carrillo J; Vergara-Alert J; Blanco J
    Sci Rep; 2021 Jan; 11(1):2608. PubMed ID: 33510275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A longitudinal study of SARS-CoV-2-infected patients reveals a high correlation between neutralizing antibodies and COVID-19 severity.
    Legros V; Denolly S; Vogrig M; Boson B; Siret E; Rigaill J; Pillet S; Grattard F; Gonzalo S; Verhoeven P; Allatif O; Berthelot P; Pélissier C; Thiery G; Botelho-Nevers E; Millet G; Morel J; Paul S; Walzer T; Cosset FL; Bourlet T; Pozzetto B
    Cell Mol Immunol; 2021 Feb; 18(2):318-327. PubMed ID: 33408342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SARS-CoV-2 infection induces sustained humoral immune responses in convalescent patients following symptomatic COVID-19.
    Wu J; Liang B; Chen C; Wang H; Fang Y; Shen S; Yang X; Wang B; Chen L; Chen Q; Wu Y; Liu J; Yang X; Li W; Zhu B; Zhou W; Wang H; Li S; Lu S; Liu D; Li H; Krawczyk A; Lu M; Yang D; Deng F; Dittmer U; Trilling M; Zheng X
    Nat Commun; 2021 Mar; 12(1):1813. PubMed ID: 33753738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical course impacts early kinetics,magnitude, and amplitude of SARS-CoV-2 neutralizing antibodies beyond 1 year after infection.
    Pradenas E; Trinité B; Urrea V; Marfil S; Tarrés-Freixas F; Ortiz R; Rovirosa C; Rodon J; Vergara-Alert J; Segalés J; Guallar V; Valencia A; Izquierdo-Useros N; Noguera-Julian M; Carrillo J; Paredes R; Mateu L; Chamorro A; Toledo R; Massanella M; Clotet B; Blanco J
    Cell Rep Med; 2022 Feb; 3(2):100523. PubMed ID: 35233547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Robust neutralizing antibodies to SARS-CoV-2 infection persist for months.
    Wajnberg A; Amanat F; Firpo A; Altman DR; Bailey MJ; Mansour M; McMahon M; Meade P; Mendu DR; Muellers K; Stadlbauer D; Stone K; Strohmeier S; Simon V; Aberg J; Reich DL; Krammer F; Cordon-Cardo C
    Science; 2020 Dec; 370(6521):1227-1230. PubMed ID: 33115920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. B careful: Humoral responses and COVID-19 severity.
    Fanous H; Guerrero-Pena A; Pillai A
    Sci Immunol; 2020 Dec; 5(54):. PubMed ID: 33277373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative SARS-CoV-2 Serology in Children With Multisystem Inflammatory Syndrome (MIS-C).
    Rostad CA; Chahroudi A; Mantus G; Lapp SA; Teherani M; Macoy L; Tarquinio KM; Basu RK; Kao C; Linam WM; Zimmerman MG; Shi PY; Menachery VD; Oster ME; Edupuganti S; Anderson EJ; Suthar MS; Wrammert J; Jaggi P
    Pediatrics; 2020 Dec; 146(6):. PubMed ID: 32879033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative analyses of SARS-CoV-2 binding (IgG, IgM, IgA) and neutralizing antibodies from human serum samples.
    Mazzini L; Martinuzzi D; Hyseni I; Benincasa L; Molesti E; Casa E; Lapini G; Piu P; Trombetta CM; Marchi S; Razzano I; Manenti A; Montomoli E
    J Immunol Methods; 2021 Feb; 489():112937. PubMed ID: 33253698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discrete SARS-CoV-2 antibody titers track with functional humoral stability.
    Bartsch YC; Fischinger S; Siddiqui SM; Chen Z; Yu J; Gebre M; Atyeo C; Gorman MJ; Zhu AL; Kang J; Burke JS; Slein M; Gluck MJ; Beger S; Hu Y; Rhee J; Petersen E; Mormann B; Aubin MS; Hasdianda MA; Jambaulikar G; Boyer EW; Sabeti PC; Barouch DH; Julg BD; Musk ER; Menon AS; Lauffenburger DA; Nilles EJ; Alter G
    Nat Commun; 2021 Feb; 12(1):1018. PubMed ID: 33589636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of neutralizing antibody responses against SARS-CoV-2 in COVID-19 patients.
    Teresa Valenzuela M; Urquidi C; Rodriguez N; Castillo L; Fernández J; Ramírez E
    J Med Virol; 2021 Jul; 93(7):4334-4341. PubMed ID: 33713457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Limited window for donation of convalescent plasma with high live-virus neutralizing antibody titers for COVID-19 immunotherapy.
    Gontu A; Srinivasan S; Salazar E; Nair MS; Nissly RH; Greenawalt D; Bird IM; Herzog CM; Ferrari MJ; Poojary I; Katani R; Lindner SE; Minns AM; Rossi R; Christensen PA; Castillo B; Chen J; Eagar TN; Yi X; Zhao P; Leveque C; Olsen RJ; Bernard DW; Gollihar J; Kuchipudi SV; Musser JM; Kapur V
    Commun Biol; 2021 Feb; 4(1):267. PubMed ID: 33627795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The kinetics of humoral response and its relationship with the disease severity in COVID-19.
    Ren L; Zhang L; Chang D; Wang J; Hu Y; Chen H; Guo L; Wu C; Wang C; Wang Y; Wang Y; Wang G; Yang S; Dela Cruz CS; Sharma L; Wang L; Zhang D; Wang J
    Commun Biol; 2020 Dec; 3(1):780. PubMed ID: 33311543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans.
    Seow J; Graham C; Merrick B; Acors S; Pickering S; Steel KJA; Hemmings O; O'Byrne A; Kouphou N; Galao RP; Betancor G; Wilson HD; Signell AW; Winstone H; Kerridge C; Huettner I; Jimenez-Guardeño JM; Lista MJ; Temperton N; Snell LB; Bisnauthsing K; Moore A; Green A; Martinez L; Stokes B; Honey J; Izquierdo-Barras A; Arbane G; Patel A; Tan MKI; O'Connell L; O'Hara G; MacMahon E; Douthwaite S; Nebbia G; Batra R; Martinez-Nunez R; Shankar-Hari M; Edgeworth JD; Neil SJD; Malim MH; Doores KJ
    Nat Microbiol; 2020 Dec; 5(12):1598-1607. PubMed ID: 33106674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expansion of SARS-CoV-2-Specific Antibody-Secreting Cells and Generation of Neutralizing Antibodies in Hospitalized COVID-19 Patients.
    Varnaitė R; García M; Glans H; Maleki KT; Sandberg JT; Tynell J; Christ W; Lagerqvist N; Asgeirsson H; Ljunggren HG; Ahlén G; Frelin L; Sällberg M; Blom K; Klingström J; Gredmark-Russ S
    J Immunol; 2020 Nov; 205(9):2437-2446. PubMed ID: 32878912
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A majority of uninfected adults show preexisting antibody reactivity against SARS-CoV-2.
    Majdoubi A; Michalski C; O'Connell SE; Dada S; Narpala S; Gelinas J; Mehta D; Cheung C; Winkler DF; Basappa M; Liu AC; Görges M; Barakauskas VE; Irvine M; Mehalko J; Esposito D; Sekirov I; Jassem AN; Goldfarb DM; Pelech S; Douek DC; McDermott AB; Lavoie PM
    JCI Insight; 2021 Apr; 6(8):. PubMed ID: 33720905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Titers of Neutralizing Antibodies against SARS-CoV-2 Are Independent of Symptoms of Non-Severe COVID-19 in Young Adults.
    Jonsdottir HR; Bielecki M; Siegrist D; Buehrer TW; Züst R; Deuel JW
    Viruses; 2021 Feb; 13(2):. PubMed ID: 33673067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody affinity maturation and plasma IgA associate with clinical outcome in hospitalized COVID-19 patients.
    Tang J; Ravichandran S; Lee Y; Grubbs G; Coyle EM; Klenow L; Genser H; Golding H; Khurana S
    Nat Commun; 2021 Feb; 12(1):1221. PubMed ID: 33619281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Virological and immunological features of SARS-CoV-2-infected children who develop neutralizing antibodies.
    Cotugno N; Ruggiero A; Bonfante F; Petrara MR; Zicari S; Pascucci GR; Zangari P; De Ioris MA; Santilli V; Manno EC; Amodio D; Bortolami A; Pagliari M; Concato C; Linardos G; Campana A; Donà D; Giaquinto C; ; Brodin P; Rossi P; De Rossi A; Palma P
    Cell Rep; 2021 Mar; 34(11):108852. PubMed ID: 33730580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Persisting Neutralizing Activity to SARS-CoV-2 over Months in Sera of COVID-19 Patients.
    Flehmig B; Schindler M; Ruetalo N; Businger R; Bayer M; Haage A; Kirchner T; Klingel K; Normann A; Pridzun L; Tougianidou D; Ranke MB
    Viruses; 2020 Nov; 12(12):. PubMed ID: 33260809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dynamics of neutralizing antibody responses to SARS-CoV-2 in patients with COVID-19: an observational study.
    Xu X; Nie S; Wang Y; Long Q; Zhu H; Zhang X; Sun J; Zeng Q; Zhao J; Liu L; Li L; Huang A; Hou J; Hou FF
    Signal Transduct Target Ther; 2021 May; 6(1):197. PubMed ID: 34006847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 65.